![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5J |
Gene summary for ATP5J |
![]() |
Gene information | Species | Human | Gene symbol | ATP5J | Gene ID | 522 |
Gene name | ATP synthase peripheral stalk subunit F6 | |
Gene Alias | ATP5 | |
Cytomap | 21q21.3 | |
Gene Type | protein-coding | GO ID | GO:0002027 | UniProtAcc | P18859 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
522 | ATP5J | GSM4909281 | Human | Breast | IDC | 4.80e-16 | -3.97e-01 | 0.21 |
522 | ATP5J | GSM4909282 | Human | Breast | IDC | 2.12e-16 | -3.97e-01 | -0.0288 |
522 | ATP5J | GSM4909285 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.21 |
522 | ATP5J | GSM4909286 | Human | Breast | IDC | 2.44e-15 | -3.97e-01 | 0.1081 |
522 | ATP5J | GSM4909287 | Human | Breast | IDC | 2.62e-21 | -3.97e-01 | 0.2057 |
522 | ATP5J | GSM4909288 | Human | Breast | IDC | 6.30e-05 | -3.97e-01 | 0.0988 |
522 | ATP5J | GSM4909289 | Human | Breast | IDC | 2.23e-03 | -3.97e-01 | 0.1064 |
522 | ATP5J | GSM4909290 | Human | Breast | IDC | 2.97e-15 | -3.97e-01 | 0.2096 |
522 | ATP5J | GSM4909291 | Human | Breast | IDC | 2.37e-12 | -3.97e-01 | 0.1753 |
522 | ATP5J | GSM4909293 | Human | Breast | IDC | 4.80e-16 | -3.97e-01 | 0.1581 |
522 | ATP5J | GSM4909294 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.2022 |
522 | ATP5J | GSM4909295 | Human | Breast | IDC | 1.09e-09 | -3.97e-01 | 0.0898 |
522 | ATP5J | GSM4909296 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.1524 |
522 | ATP5J | GSM4909297 | Human | Breast | IDC | 2.12e-16 | -3.97e-01 | 0.1517 |
522 | ATP5J | GSM4909298 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.1551 |
522 | ATP5J | GSM4909299 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.035 |
522 | ATP5J | GSM4909300 | Human | Breast | IDC | 1.54e-08 | -3.97e-01 | 0.0334 |
522 | ATP5J | GSM4909301 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.1577 |
522 | ATP5J | GSM4909302 | Human | Breast | IDC | 5.30e-21 | -3.97e-01 | 0.1545 |
522 | ATP5J | GSM4909303 | Human | Breast | IDC | 1.27e-05 | -3.97e-01 | 0.0438 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501427 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
hsa0541528 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
hsa0471429 | Prostate | Tumor | Thermogenesis | 110/1791 | 232/8465 | 1.56e-19 | 3.96e-18 | 2.46e-18 | 110 |
hsa0502227 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
hsa0501237 | Prostate | Tumor | Parkinson disease | 144/1791 | 266/8465 | 3.33e-33 | 1.10e-30 | 6.83e-31 | 144 |
hsa0502036 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
hsa0501636 | Prostate | Tumor | Huntington disease | 150/1791 | 306/8465 | 2.72e-28 | 2.25e-26 | 1.40e-26 | 150 |
hsa0019036 | Prostate | Tumor | Oxidative phosphorylation | 83/1791 | 134/8465 | 7.47e-25 | 4.12e-23 | 2.55e-23 | 83 |
hsa0501036 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
hsa0520837 | Prostate | Tumor | Chemical carcinogenesis - reactive oxygen species | 113/1791 | 223/8465 | 5.17e-23 | 1.90e-21 | 1.18e-21 | 113 |
hsa0501436 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
hsa0541536 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
hsa0471437 | Prostate | Tumor | Thermogenesis | 110/1791 | 232/8465 | 1.56e-19 | 3.96e-18 | 2.46e-18 | 110 |
hsa0502236 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
hsa0501212 | Stomach | GC | Parkinson disease | 73/708 | 266/8465 | 7.15e-21 | 7.63e-19 | 5.37e-19 | 73 |
hsa0520812 | Stomach | GC | Chemical carcinogenesis - reactive oxygen species | 65/708 | 223/8465 | 3.46e-20 | 2.72e-18 | 1.91e-18 | 65 |
hsa0019012 | Stomach | GC | Oxidative phosphorylation | 49/708 | 134/8465 | 4.24e-20 | 2.72e-18 | 1.91e-18 | 49 |
hsa0502012 | Stomach | GC | Prion disease | 68/708 | 273/8465 | 4.69e-17 | 2.50e-15 | 1.76e-15 | 68 |
hsa0541512 | Stomach | GC | Diabetic cardiomyopathy | 56/708 | 203/8465 | 2.48e-16 | 1.14e-14 | 8.00e-15 | 56 |
hsa0501612 | Stomach | GC | Huntington disease | 69/708 | 306/8465 | 6.71e-15 | 2.68e-13 | 1.89e-13 | 69 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ATP5J | SNV | Missense_Mutation | novel | c.290N>T | p.Thr97Ile | p.T97I | P18859 | protein_coding | deleterious(0.05) | possibly_damaging(0.481) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP5J | SNV | Missense_Mutation | rs140201687 | c.88N>T | p.Arg30Trp | p.R30W | P18859 | protein_coding | tolerated(0.08) | benign(0.019) | TCGA-AX-A06D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
ATP5J | SNV | Missense_Mutation | c.56N>A | p.Ser19Tyr | p.S19Y | P18859 | protein_coding | deleterious(0) | possibly_damaging(0.747) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.185N>A | p.Arg62Gln | p.R62Q | P18859 | protein_coding | tolerated(0.32) | benign(0.083) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | novel | c.106A>C | p.Thr36Pro | p.T36P | P18859 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ATP5J | SNV | Missense_Mutation | novel | c.271N>T | p.Gly91Cys | p.G91C | P18859 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-85-A4QQ-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |